ANZMTG - Australia and New Zealand Melanoma Trials Group Home | Login
ANZMTG - Australia and New Zealand Melanoma Trials Group
 

LOGIN


Please enter your username and password.


Username

Password


  
ANZMTG
Printer Friendly

Publications, Posters, and Presentations

*2016      *2015      *2014      *2013      *2012      *2011      *2010     *2009  

2016

Online Presentations

  • Moncrieff, M et al Preliminary feasibility data from the Melanoma Margins Trial (MelMarT) Pilot Study: Australian and New Zealand Melanoma Trials Group (ANZMTG) Study 03.12 Society of Surgical Oncology (SSO) Annual Cancer Symposium, 2nd – 5th March 2016, Boston, USA [submitted]

Return to top

2015

Original Research Articles

  • Henderson M, Burmeister B, Ainslie J, Fisher R, Di Iulio J, Smithers M, Hong A, Shannon K, Scolyer R, Carruthers S, Coventry B, Babington S, Duprat J, Hoekstra H, Thompson J.   Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. The Lancet Oncology 2015. doi:10.1016/S1470-2045(15)00187-4
  • Dieng M., Kasparian N. A., Morton R. l., Mann G. l., Butow P., Menzies S., Costa D., Cust A. E. The Melanoma care study: protocol of a randomised controlled trial of a psychoeducational intervention for melanoma survivors at high risk of developing new primary disease. BMC Psychology 2015 3:23
  • Santos ED, Green JA, Bhandari N, Hong A, Guitera P, Fogarty GB. Tangential Volumetric Modulated Radiotherapy – A New Technique for Large Scalp Lesions with a Case Study in Lentigo Maligna Int. J. BioAutomation, 2015, 19(2), 223-236
  • Keen, CE. WBRT benefits for melanoma patients with brain metastases: Status of a clinical trial. Applied Radiation Oncology May 18 2015
  • Fogarty GB, Hong A, Jacobsen KD, Reisse C, Burmeister B, Haydu L, Dhillon H, Steel V, Shivalingam B, Drummond K, Vardy J, Nowak A, Hruby G, Scolyer R, Mandel C, Thompson JF. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Research Notes 2015 8:192
  • Fogarty GB, Hong A, Paton E, Li P. In Regard to Sahgul et al. International Journal of Radiation Oncology, Biology, Physics May 2015
  • Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassell JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. ‘Nivolumab in Previously Untreated Melanoma without BRAF mutation.’ N Engl J Med 2014 2015 Jan 22;372(4):320-30 IF 54.42

Oral Presentations

  • Hong, A. (2015, October). Randomised Trials to Define the Role of Radiation Therapy in Melanoma. Presented at Veneto Institute of Oncology meets Melanoma Institute Australia, Padua, Italy.
  • Fogarty GB, Hong A, Foote M, Jacobsen KD, Riesse C, Guitera P, Wang T, Middleton MR, Paton E, Burmeister B Ongoing high quality randomised trials are helping define the role of Radiotherapy in melanoma COSA ASM 2015, 17th November 2015, Hobart TAS (Oral presentation – accepted)
  • Fogarty GB, Hong A, Jacobsen KD, Reisse C, Shivalingam B, Middleton MR, Paton E, Wijaya H, Burmeister B  An update on the ANZMTG 01.07 WBRTMel trial – The role of Adjuvant whole brain radiotherapy for patients with melanoma brain metastases; COSA Annual Scientific Meeting 2015, 17th November 2015, Hobart TAS (Poster presentation - accepted)
  • Fogarty G et al. A Randomised Controlled Trial of Photodynamic Therapy versus Radiotherapy for Superficial Skin Cancer – The “PDRT” Study, Global Controversies and Advances in Skin Cancer, October 2015, Brisbane, Australia (Oral presentation)
  • Hong A Change in the hippocampal volume after whole brain radiation therapy with or without hippocampal avoidance technique American Society for Radiation Oncology (ASTRO) Annual Meeting, 18th – 21st October 2015, San Antonio, USA (Poster presentation -accepted)
  • Hong A Change in the hippocampal volume after whole brain radiation therapy with or without hippocampal avoidance technique 11th EADO Congress and 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Center, 28th – 31st October 2015, Marseille, France (Poster presentation - accepted)
  • Foote M, Smithers M, Thompson J, Hong A, Fogarty G, Scolyer R, Henderson M, Estall V, Potter A, Paton E, Lucas A, Barker C, Burmeister B. TROG 08.09 ANZMTG 01.09 An International Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck., Global Controversies and Advances in Skin Cancer, October 2015, Brisbane, Australia (Oral presentation)
  • Hong A, Jacobsen KD, Reisse C, Shivalingam B, Middleton MR, Paton E, Wijaya H, Burmeister B  An update on the ANZMTG 01.07 WBRTMel trial – The role of Adjuvant whole brain radiotherapy for patients with melanoma brain metastases; Nordic Melanoma Meeting 2015, Gothenburg Sweden Friday 4th September 2015 (Oral presentation)
  • Fogarty GB, Hong A, Foote M, Jacobsen KD, Riesse C, Guitera P, Wang T, Middleton MR, Paton E, Burmeister B Ongoing high quality randomised trials are helping define the role of Radiotherapy in melanoma; Nordic Melanoma Meeting 2015, Gothenburg Sweden Friday 4th September 2015 (Oral presentation)
  • Spillane, A et al. Patients will benefit from a standardised approach to metastatic melanoma to the inguinal lymph nodes: an overview of the ANZMTG 01.12 EAGLE FM trial, 11th Nordic Melanoma Meeting 2015, 2 – 4 September 2015, Gothenburg, Sweden (Oral Presentation)
  • Spillane, A et al. ANZMTG 01.12 EAGLE FM trial – Evaluation of Groin Lymphadenectomy Extent For metastatic Melanoma; A randomised phase III trial investigating Inguinal or Ilio-inguinal Lymphadenectomy for patients with metastatic melanoma to groin lymph nodes with no evidence of pelvic disease on PET/CT Scan, Inaugural Melanoma & Skin Cancer Special Interest Group (MELSIG) Mini-Symposium, 16th July 2015, Sydney, Australia (Oral Presentation)
  • Foote, M. A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (ANZMTG 01.09; TROG 08.09), TROG Annual Scientific Meeting, 24 March 2015, Newcastle, Australia. (Oral presentation)
  • Saw, R et al. ANZMTG 02.09 Mel-D trial – Vitamin D following primary treatment of melanoma at high risk of recurrence: A pilot placebo controlled randomised phase II trial, Inaugural Melanoma & Skin Cancer Special Interest Group (MELSIG) Mini-Symposium, 16th July 2015, Sydney, Australia (Oral Presentation)
  • Wang et al. ANZMTG 02.14 – What dose of palliative radiotherapy is best for patients already on combination BRAF MEK inhibitor therapy; An update on the phase 2 dose escalation CombiRT trial Inaugural Melanoma & Skin Cancer Special Interest Group (MELSIG) Mini-Symposium, 16th July 2015, Sydney, Australia [Oral Presentation]
  • Guitera et al. ANZMTG 02.12 RADICAL trial – Comparing imiquimod cream to radiotherapy for patients with complex Lentigo maligna Inaugural Melanoma & Skin Cancer Special Interest Group (MELSIG) Mini-Symposium, 16th July 2015, Sydney, Australia [Oral Presentation]
  • Spillane et al. ANZMTG 03.12 – What is the most safe wide local excision margin for patients with primary cutaneous melanoma? An update on the ANZMTG 03.12 MelMarT trial Inaugural Melanoma & Skin Cancer Special Interest Group (MELSIG) Mini-Symposium, 16th July 2015, Sydney, Australia [Oral Presentation]
  • Fogarty GB ANZMTG 01.07- An update on the WBRTMel trial; Adjuvant whole brain radiotherapy – wisdom requires more data, and less dogma Inaugural Melanoma & Skin Cancer Special Interest Group (MELSIG) Mini-Symposium, 16th July 2015, Sydney, Australia
  • Guitera P. Introduction to RADICAL and Reflectance Confocal Microscopy (RCM) investigator training Dermatology Unit, Royal Adelaide Hospital, 19th May 2015, Adelaide Australia [Oral Presentation]
  • Guitera P. Introduction to RADICAL and Reflectance Confocal Microscopy (RCM) investigator training Victorian Melanoma Service, The Alfred Hospital, 6th May 2015, Melbourne Australia [Oral Presentation]
  • Burmeister B. The Role of Radiotherapy in Melanoma: highlighting the role of ANZMTG and the ANZMTG 01.02 trial results. Santa Casa Hospital, 23 April 2015, Porto Alegre, Brasil [Oral Presentation]
  • Fogarty GB, 08.05 (WBRT): Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. TROG 27th Annual Scientific Meeting, Newcastle, Australia, 24th – 26th March 2015 (Oral presentation)
  • Fogarty, GB. ABC Study - Nivolumab in melanoma patients with brain metastases – the rationale for the WBRT arm (New Trial Discussion), TROG Annual Scientific Meeting, 24 March 2015, Newcastle, Australia. (Oral presentation)
  • Moncrieff M. et al. MelMart Phase III, Multi-centre Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma: Melanoma Margins Trial. Society of Surgical Oncology (SSO) Annual Cancer Symposium, 25th – 28th March 2015, Texas, USA [Oral Presentation]
  • Guitera P. Reflectance Confocal Microscopy and taking the guess out of skin radiotherapy fields The Trans Tasman Radiation Oncology Group (TROG) 27th Annual Scientific Meeting, 25 March 2015, Newcastle, Australia. [Oral Presentation]
  • Johnston, M. Prospective multisite evaluation of the roles of 18F-FDG PET and SLN mapping ± biopsy in the diagnostic work-up of MCC(New proposal) (Cat B), TROG Annual Scientific Meeting, 24 March 2015, Newcastle, Australia. (Oral presentation)
  • Fogarty, GB. ABC Study - Nivolumab in melanoma patients with brain metastases – the rationale for the WBRT arm (New Trial Discussion), TROG Annual Scientific Meeting, 24 March 2015, Newcastle, Australia. (Oral presentation)
  • Foote, M. A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (ANZMTG 01.09; TROG 08.09), TROG Annual Scientific Meeting, 24 March 2015, Newcastle, Australia. (Oral presentation)
  • Wang T. et al. Phase I study evaluating safety of combining BRAF and MEK inhibitors with palliative radiotherapy for metastatic melanoma Trans Tasman Radiation Oncology Group (TROG) 27th Annual Scientific Meeting, 24th March, Newcastle, Australia [Oral Presentation]

Poster Presentations

  • Hong A Change in the hippocampal volume after whole brain radiation therapy with or without hippocampal avoidance technique American Society for Radiation Oncology (ASTRO) Annual Meeting, 18th – 21st October 2015, San Antonio, USA (Poster presentation)
  • Hong A Change in the hippocampal volume after whole brain radiation therapy with or without hippocampal avoidance technique 11th EADO Congress and 8th World Meeting of Interdisciplinary Melanoma/Skin Cancer Center, 28th – 31st October 2015, Marseille, France (Poster presentation)
  • Foote, M, Smithers, M, Thompson, J, Hong, A, Fogarty, G, Scolyer, R, Henderson, M, Estall, V, Potter, A, Paton, E, Lucas, A, Barker, C, Burmeister, B. TROG 08.09 ANZMTG 01.09 An International Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck., ACTA 2015 International Clinical Trials Symposium, October 2015, Sydney, Australia (Poster)

Media

  • AAP, 2015, 'FED: Skin cancer trials need Aussies: expert', AAP Newswire 19 November.
  • Daily Liberal, 2015, 'Cancer trial lacks volunteers', Daily Liberal 20 November, p. 7.
  • Western Advocate, 2015, 'Cancer trial lacks volunteers', Western Advocate 20 November, p. 12.
  • Herald Sun, 2015, 'Research: Locals shun skin cancer trials', Herald Sun 20 November, p. 41.

Return to top

2014

Original Research Articles

  • Saw, R., Armstrong, B., Mason, R., Morton, R., Shannon, K., Spillane, A., Stretch, J., Thompson, T. Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: A placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D), BMC Cancer 2014 Oct 24
  • Winstanley JB, Young TE, Boyle FM, Bergenmar M, Bottomley A, Burmeister B, Campana LG, Garioch JJ, King M, Nikolic DV, van de Poll-Franse LV, Saw R, Thompson JF, White EG; on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group. Cross-cultural development of a quality of life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module, Melanoma Res. 2014 Oct 16
  • De Sousa, S, Long GV, Tonks K. ‘Ipilimumab-induced hypophysitis: early Australian experience.’ Med J Aust 2014 Aug 18;201(4):198-9. IF 3.789
  • Du Four S, Hong A, Chan M, Charakidis M, Duerinck J, Wilgenhof S, Wang W, Feng L, Michotte A, Okera M, Shivalingam B, Fogarty G, Kefford R and Neyns B. Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients, Case Reports in Oncological Medicine 2014 Jul 1
  • Gerald B Fogarty, Angela Hong, Kari D Jacobsen, Claudius H Reisse, Brindha Shivalingam, Bryan Burmeister, Lauren E Haydu, et al. Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible, BMC Research Notes 2014 Jun 30
  • Guitera P, Haydu LE, Menzies SW, Scolyer RA, Hong A, Fogarty GB, Gallardo F, Segura S. Surveillance for treatment failure of lentigo maligna with dermoscopy and in vivo confocal microscopy: new descriptors. Br J Dermatol. 2014 Jun; 170(6):1305-12
  • Hong A, Chao Suo, Valenzuela M, Haydu L, Jacobsen K, Reisse C, Fogarty G, Low incidence of melanoma brain metastasis in the hippocampus, Radiotherapy and Oncology, 2014 Apr
  • Fogarty G, Hong A , Radiation Therapy for Advanced and Metastatic Melanoma, Journal of Surgical Oncology, 2014 Mar
  • Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ, Kashani-Sabet M, Smithers BM, Paul E,  Kraybill WG, McKinnon JG, Wang H, Elashoff R, and Faries MB. Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma, New England Journal of Medicine. 2014 Feb 13
  • Zalaudek I., Cota C., Ferrara G., Moscarella E., Guitera P., Longo C., Piana S., Argenziano G. Flat pigmented macules on sun-damaged skin of the head/neck: junctional nevus, atypical lentiginous nevus, or melanoma in situ? Clin Dermatol. 2014 Jan-Feb; 32(1):88-93
  • Spillane, A. Pasquali, S., Haydu, L. and Thompson, J. Patterns of recurrence and survival after lymphadenectomy in melanoma patients: clarifying the effects of timing of surgery and lymph node tumor burden. Annals of Surgical Oncology 2014 Jan
  • Fogarty G.B., Hong A., Scolyer R.A., Lin E., Haydu L., Guitera P., Thompson J. Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. Br J Dermatol. 2014 Jan; 170(1):52-8

Oral Presentations

  • Saw, R. The person at risk of melanoma:Vitamin D study & prevention; Australia and New Zealand Melanoma Trials Group (ANZMTG) Annual Scientific Meeting, 20 November 2013, Brisbane, Australia. [Oral presentation]
  • Paton E. ANZMTG 01.12 EAGLE FM trial – Evaluation of Groin Lymphadenectomy Extent For metastatic Melanoma; A randomised phase III trial investigating Inguinal or Ilio-inguinal Lymphadenectomy for patients with metastatic melanoma to groin lymph nodes with no evidence of pelvic disease on PET/CT Scan. National Melanoma Conference, 11 October 2014, Perth, Australia. [Oral presentation]
  • Long G. ANZMTG 01.14 ABC Nivo trial - A phase II study of nivolumab and nivolumab in combination with ipilimumab in patients with melanoma brain metastases. National Melanoma Conference, 11 October 2014, Perth, Australia. [Oral presentation]
  • Wang T. et al. An open label, single arm, phase I/II multicentre study to evaluate the safety and efficacy of the combination of Dabrafenib, Trametinib and palliative radiotherapy in patients with unresectable Stage IIIc and Stage IV BRAF V600E/K mutation-positive cutaneous melanoma (CombiRT) Australia and New Zealand Melanoma Trials Group Annual Scientific Meeting, 9th October, Perth, Australia [Oral Presentation]
  • Fogarty G. A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails (RADICAL),  Australian and New Zealand Melanoma Trials Group Annual Scientific Meeting, 9th October 2014 [Oral Presentation]
  • Henderson M. et al. MelMart Phase III, Multi-centre Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma: Melanoma Margins Trial. Australia and New Zealand Melanoma Trials Group Annual Scientific Meeting, 9th October, Perth, Australia [Oral Presentation]
  • Guitera P. A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails, 2nd National Scott Kirkdale Melanoma Research Centre (SKMRC) Melanoma Conference, 9th October 2014, Perth Australia [Oral Presentation]
  • K Drummond, G B Fogarty, A Hong, K Dolven-Jacobsen, C H Reisse, B Burmesiter, E Paton, V Steel, L Haydu, H Dhillon, B Shivalingam, J Vardy, A Nowak, G Hruby, R Scolyer, C Mandel, J F Thompson. ANZMTG 01.07 WBRTMel: Randomised Trial of Whole Brain Radiotherapy in Melanoma Brain Metastases – First Interim Analysis, Neurosurgical Society Australia Annual Scientific Meeting (NSA ASM), 2nd-4th October 2014, Perth, Australia, (Oral Presentation).
  • K Dolvern-Jacobsen, G B Fogarty, A Hong, C H Reisse, E Paton, V Steel, V Neve, B Burmeister, J F Thompson. ANZMTG 01.07 WBRTMel: Whole Brain Radiotherapy Following Local Treatment of Melanoma Brain Metastases, Nordic Melanoma Group, Turku, Finland, 4th-5th September 2014, (Oral Presentation).
  • K Dolven –Jacobsen, G B Fogarty, C H Resisse, E Paton, V Steel, J F Thompson. Australia and New Zealand Melanoma Trials Group (ANZMTG): The Importance of Successful Collaborations, Nordic Melanoma Group, Turku, Finland, 4th-5th September 2014, (Oral Presentation).
  • Fogarty GB. Clinical Trials in advanced melanoma: Key Trials in Radiation Oncology. Melanoma Institute Australia Research Retreat, 29th August 2014, Sydney, Australia [Oral Presentation]
  • Henderson M. et al. MelMart Phase III, Multi-centre Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma: Melanoma Margins Trial. Melanoma Institute Australia Research Retreat, 29th August 2014, Sydney, Australia [Oral Presentation]
  • Guitera P. A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails (RADICAL), Melanoma Institute Australia Research Retreat, 29th August 2014, Sydney, Australia [Oral Presentation]
  • Long G. Clinical Trials in advanced melanoma: Trials to open (6-12 months). Melanoma Institute Australia Research Retreat, 29th August 2014, Sydney, Australia [Oral Presentation]
  • Spillane A. Clinical Trials in advanced melanoma: Key Trials in Surgery. Melanoma Institute Australia Research Retreat, 29th August 2014, Sydney, Australia [Oral Presentation]
  • Guitera P. The Australasian College of Dermatologists 47th Annual Scientific Meeting, 16th-21st May 2014, Melbourne Australia [Oral Presentation]
  • Foote, M. A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (ANZMTG 01.09; TROG 08.09), TROG Annual Scientific Meeting, April 2014, Sunshine Coast, Australia (Oral Presentation).
  • Shaw J, Boyle F, Dunn S, Butow P. Towards national education resources in clinical trials consent communication. Australian Clinical Trials Alliance Summit, 28-29 March, 2014, Melbourne, Australia. (Oral Presentation).
  • Boyle F, The clinical trials consent communication in conjunction with journal papers on the needs of patients’ with stage 3 melanoma and the issues surrounding communication about clinical trials. Melanoma Institute Australia Journal Club, 7 March 2014, Sydney, Australia. (Oral Presentation).

Poster Presentations

  • K Drummond, G B Fogarty, A Hong, K Dolven-Jacobsen, C H Reisse, B Burmeister, V Steel, L Haydu, H Dhillon, B Shivalingham, J Vardy, A Nowak, G Hruby, R Scolyer, C Mandel, J F Thompson. ANZMTG 01.07 WBRTMel: Randomised Trial of Whole Brain Radiotherapy in Melanoma Brain Metastases – First Interim Analysis, Cooperative Trials Group for Neuro-oncology Annual Scientific Meeting, Melbourne, Australia, 24th-25th October 2014 (Poster Presentation)
  • G B Fogarty, A Hong, K Dolven-Jacobsen, C H Reisse, B Burmeister, V Steel, L Haydu, H Dhillon, B Shivalingham, K Drummond, J Vardy, A Nowak, G Hruby, R Scolyer, C Mandel, J F Thompson. ANZMTG 01.07 WBRTMel: Randomised Trial of Whole Brain Radiotherapy in Melanoma Brain Metastases – First Interim Analysis, American Society for Radiation Oncology (ASTRO), San Francisco, USA, 14th-17th September 2014, (Poster Presentation)
  • Santos D., Green J. A., Bhandari N., Hong A., Guitera P., Fogarty G. Tangential Volumetric Modulated Radiotherapy Is Superior To Brachytherapy For Large Scalp Lesions - A Case Study In Lentigo Maligna. Annual Meeting Scientific Program Committee of the American Society for Radiation Oncology (ASTRO), September 2014, San Francisco, U.S.A. [Poster Presentation]

Audiovisual Recordings

  • Read RL, Spillane AJ. A minimally invasive technique for pelvic lymphadenectomy in
    patients with metastatic melanoma. Top rated videos: oral presentation. Society of Surgical Oncology, 67th Annual Cancer Symposium, Phoenix, Arizona. 12-15 March 2014 
    Video:
    https://anzmtg.org/content.aspx?page=trialvideos

Return to top

2013

Original Research Articles

  • Bogun Y, Scolyer RA, Guitera P. Asymptomatic linear pigmentation of the skin. Int J Dermatol. 2013 Aug
  • Guitera P, Moloney FJ, Menzies SW, Stretch JR, Quinn MJ, Hong A, Fogarty G, Scolyer RA. Improving management and patient care in lentigo maligna by mapping with in vivo confocal microscopy. JAMA Dermatol. 2013 Jun
  • Winstanley JB, White EG, Boyle FM, Thompson JF. What are the pertinent quality of life issues for melanoma cancer patients? Aiming for the development of a new module to accompany the EORTC core questionnaire, Melanoma Res. 2013 Apr
  • Awad R, G Fogarty, A Hong, P Kelly P, D Ng, D Santos and L Haydu. Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases - the first Australian experience. Radiation Oncology 2013 Mar 18
  • Winstanley JB, Saw R, Boyle FM, Thompson JF. The FACT-Melanoma Quality of Life Instrument: Comparison of a five and four point response scale using the Rasch Measurement Model, Melanoma Res. 2013 Feb

Conference Abstracts/Proceedings

  • Spillane A., Allan C., Haydu L., Paton E., Lucas A., The ideal extent of groin lymphadenectomy for metastatic melanoma to inguinal lymph nodes is still controversial: feasibility of the proposed ANZMTG EAGLE FM trial. Journal of the Deutschen Dermatologischen Gesellschaft 2013, [abstract]
  • G Fogarty et al, Accrual to a randomised trial of whole brain radiotherapy in melanoma brain metastases is feasible. Journal of the Deutschen Dermatologischen Gesellschaft 2013, [abstract]
  • M Foote et al, ANZMTG 01.09 A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck. Journal of the Deutschen Dermatologischen Gesellschaft 2013, [abstract]
  • R Morton et al, Methods for the economic evaluation of whole brain radiotherapy alongside a randomised controlled trial. Journal of the Deutschen Dermatologischen Gesellschaft 2013, [abstract]
  • P Guitera et al, ANZMTG 02.12 A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails (RADICAL Trial). Journal of the Deutschen Dermatologischen Gesellschaft 2013, [abstract]
  • Henderson MA, Burmeister BH,  Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01). Journal of the Deutschen Dermatologischen Gesellschaft 2013, [abstract]
  • Henderson MA, Burmeister BH,  Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01). Journal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 31, No 15_suppl (May 20 Supplement), 2013: 9001.

Oral Presentations

  • P Guitera et al, ANZMTG 02.12 A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails. Global Controversies of Skin Cancer Conference, 21-23 November 2013, Brisbane, QLD (Oral Presentation)
  • Spillane A., Allan C., Haydu L., Paton E., Lucas A. We need a trial to evaluate whether patients with involved inguinal lymph nodes should have inguinal or ilioinguinal lymphadenectomy; an overview of the proposed trial ANZMTG 01.12 EAGLE FM Protocol. Global Controversies of Skin Cancer Conference, 21-23 November 2013, Brisbane, QLD (Oral Presentation)
  • M Foote et al, TROG 08.09 ANZMTG 01.09 An international randomised trial of postoperative radiation therapy following wide excision of neurotropic melanoma of the head and neck. Global Controversies of Skin Cancer Conference, 21-23 November 2013, Brisbane, QLD (Oral Presentation)
  • G Fogarty et al, Accrual to a randomised trial of whole brain radiotherapy in melanoma brain metastases is feasible, Global Controversies of Skin Cancer Conference, 21-23 November  2013, Brisbane, QLD (Oral Presentation)
  • M Henderson et al, ANZMTG 03.12 Melanoma Excision Margins Trial - A Phase III, multi-centre randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma. Global Controversies of Skin Cancer Conference, 21-23 November  2013, Brisbane, QLD (Oral Presentation)
  • Spillane A., Allan C., Evaluation of Groin Lymphadenectomy Extent For metastatic Melanoma The EAGLE FM Study (ANZMTG 01.12) – Trial Update; Australia and New Zealand Melanoma Trials Group (ANZMTG) Annual Scientific Meeting, 20 November 2013, Brisbane, Australia. [Oral presentation]
  • M Henderson. A randomised clinical trial of surgery versus surgery plus adjuvant radiotherapy for regional control in patients with completely resected macroscopic nodal metastatic melanoma. ANZMTG ASM, 20 November 2013, Brisbane, Australia (Oral Presentation)
  • Henderson M. et al. MelMart Phase III, Multi-centre Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma: Melanoma Margins Trial. Global Controversies in Skin Cancer, 20th November 2013, Brisbane, Australia [Oral Presentation]
  • G Fogarty et al. ANZMTG 01.07 Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - A randomised phase III trial & overview of current sub-studies. ANZMTG ASM, 20 November 2013, Brisbane, Australia (Oral Presentation)
  • M Foote et al, ANZMTG 01.09 A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck. ANZMTG ASM, 20 November 2013, Brisbane, Australia (Oral Presentation)
  • R Saw et al, ANZMTG 02.09 Vitamin D following primary treatment of melanoma at high risk of recurrence: A pilot placebo controlled randomised phase II trial, ANZMTG ASM, 20 November 2013, Brisbane, Australia (Oral Presentation)
  • P Guitera et al, ANZMTG 02.12 A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails. ANZMTG ASM, 20 November 2013, Brisbane, Australia (Oral Presentation)
  • M Foote et al, ANZMTG 04.12 Radiotherapy followed by selective nodal dissection for high volume regional melanoma, ANZMTG ASM, 20 November 2013, Brisbane, Australia (Oral Presentation)
  • A Spillane et al, ANZMTG 01.12 Inguinal or Ilio-inguinal Lymph Node Dissection for patients with metastatic melanoma to groin lymph nodes and no evidence of pelvic disease on PET / CT Scan –  A randomised phase III trial. ANZMTG ASM, 20 November 2013, Brisbane, Australia (Oral Presentation)
  • M Henderson et al, ANZMTG 03.12 Melanoma Excision Margins Trial, ANZMTG ASM, 20 November 2013, Brisbane, Australia (Oral Presentation)
  • A Hong, Distance of melanoma metastasis to the hippocampus: estimated safety of hippocampal sparing whole brain radiation therapy, Cooperative Trials Group for Nero Oncology ASM, Sydney, Australia, 25-26th October, 2013 (Oral presentation)
  • ANZMTG 01.07 WBRTMel Trial Annual Investigators Meeting, held in London, UK, 26th July 2013 at The Mayfair Hotel.
    Conveners: G Fogarty, R Morton, E Paton
    Facilitators: E Paton, A Hong, R Morton
    Oral Presentations: E Paton, A Hong, R Morton, C Scudder
  • Henderson MA, Burmeister BH,  Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01). 8th World Congress of Melanoma, July 2013, Hamburg, Germany (Oral presentation)
  • G Fogarty et al, Accrual to a randomised trial of whole brain radiotherapy in melanoma brain metastases is feasible, World Melanoma Congress, Hamburg, Germany 20 July 2013 (Oral presentation)
  • Henderson MA, Burmeister BH,  Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Adjuvant radiotherapy after lymphadenectomy in melanoma patients: Final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01). 2013 ASCO Annual Meeting (Oral Presentation)
  • M Middleton et al. Why we need British Neurosurgeons – the ANZMTG 01/07 TROG 08/05 - Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - A randomised phase III trial, Society of British Neurological Surgeons May 24th 2013, Sheffield UK (Oral presentation)
  • P Guitera et al. In vivo Confocal Microscopy: Diagnosis of Skin Tumours - Is there a place for Confocal Microscopy in the Australian Dermatology Community? Workshop, 23 May 2013, Sydney, Australia (Oral presentation)
  • P Guitera et al. ANZMTG 02.12 A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails (RADICAL Trial).  The Australian College of Dermatology Annual General Meeting, 19th- 22nd May 2013, Sydney, Australia. (Oral presentation)
  • C Mandel, CNS melanoma metastases – update on imaging and management, Australian and New Zealand Society of Neuroradiology Annual Scientific Meeting (ANZSNR ASM), March 2013, Hobart, Australia (Oral presentation)
  • ANZMTG 01.07 WBRTMel Trial Amendment 7 Training Workshop, held in Sydney, Australia, on 25 March 2013 at Melanoma Institute Australia.
    Conveners: E Paton, G Fogarty, R Morton
    Facilitators: E Paton, G. Fogarty, R Morton
    Oral Presentations: E Paton, G.Fogarty, R Morton, E.Lin
  • B Burmeister. Whole Brain Radiotherapy Following Local Treatment of 1-3 Intracranial Metastases of Melanoma – A Phase III Trial (ANZMTG 01/07; TROG 08/05), Trans Tasman Radiation Oncology Group Annual Scientific Meeting (TROG ASM), February 2013, Wellington, New Zealand (Oral presentation)

Poster Presentations

  • Foote M et al.  Radiotherapy followed by selective nodal dissection for high volume regional melanoma – A phase II trial (REFORM). Global Controversies of Skin Cancer Conference, 21-23 November 2013, Brisbane, QLD (Poster Presentation)
  • R Morton et al, Methods for the economic evaluation of whole brain radiotherapy alongside a randomised controlled trial, Global Controversies of Skin Cancer Conference, 21-23 November  2013, Brisbane, QLD (Poster Presentation)
  • Saw R., Armstrong B. Mason R. Morton R. Thompson J. High dose vitamin D following primary treatment of melanoma at high risk of recurrence: A placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D Trial) Global Controversies of Skin Cancer Conference, 21-23 November  2013, Brisbane, QLD (Poster presentation)
  • P. Guitera et al. ANZMTG 02.12 A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails. Clinical Oncology Society of Australia Annual Scientific Meeting, November 2013, Adelaide, Australia (Poster Presentation)
  • M Foote et al, ANZMTG 01.09 A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck. Clinical Oncology Society of Australia Annual Scientific Meeting, November 2013, Adelaide, Australia (Poster Presentation)
  • G Fogarty et al, Accrual to a randomised trial of whole brain radiotherapy in melanoma brain metastases is feasible, Clinical Oncology Society of Australia Annual Scientific Meeting, November 2013, Adelaide, Australia (Poster Presentation)
  • A Spillane, C Allan, L Haydu, E Paton, A Lucas, We need a trial to evaluate whether patients with involved inguinal lymph nodes should have inguinal or ilio-inguinal lymphadenectomy; an overview of the proposed trial ANZMTG 01.12 EAGLE FM Protocol, Clinical Oncology Society of Australia Annual Scientific Meeting, November 2013, Adelaide, Australia (Poster Presentation)
  • C. Mandel. Intracranial melanoma metastases: imaging appearances and current management Royal Australian and New Zealand College of Radiology Annual Scientific Meeting (RANZCR ASM), 2013, Auckland, New Zealand (Poster Presentation)
  • A Spillane, C Allan, L Haydu, E Paton, A Lucas, The ideal extent of groin lymphadenectomy for metastatic melanoma to inguinal lymph nodes is still controversial: feasibility of the proposed ANZMTG EAGLE FM trial. 8th World Congress of Melanoma, July 2013, Hamburg, Germany (Poster presentation)
  • G Fogarty et al, Accrual to a randomised trial of whole brain radiotherapy in melanoma brain metastases is feasible, World Melanoma Congress, Hamburg, Germany 20th July 2013 (Poster presentation)
  • R Morton, Methods for the economic evaluation of whole brain radiotherapy alongside a randomised controlled trial, World Melanoma Congress, Hamburg, Germany, 20th July 2013, (Poster presentation)
  • P Guitera et al, ANZMTG 02.12 A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails (RADICAL Trial). World Melanoma Congress, Hamburg, Germany, 20th July 2013, (Poster presentation)
  • M Foote et al, ANZMTG 01.09 A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck. World Melanoma Congress, Hamburg, Germany, 20th July 2013, (Poster presentation)

Other Presentations

  • V Neve and V Steel. ANZMTG information booth and education stand. Pharmaceutical Society of Australia’s Clinical and Practice Expo, Hordern Pavilion, Sydney, 31 May - 2 June 2013
  • V Neve. ANZMTG information booth and education stand. In vivo Confocal Microscopy Workshop, 23 May 2013, Sydney, Australia

Return to top

 

2012

Original Research Articles

  • Fogarty G, Ng D, Liu G, Haydu L, Bhandari N. Volumetric modulated arc therapy is superior to conventional intensity modulated radiotherapy - a comparison among prostate cancer patients treated in an Australian centre, Radiat Oncol. 2011 Sep 5
  • Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012 Jun
  • Hong A, Fogarty G, Izard M. The role of radiation therapy in the management of metastatic melanoma in the brain. Int J Surg Oncol. 2012 Apr
  • Fogarty G, Morton RL, Vardy J, Nowak AK, Mandel C, Forder PM, Hong A, Hruby G, Burmeister B, Shivalingam B, Dhillon H, Thompson JF. Whole Brain Radiotherapy after local treatment of brain metastases in melanoma patients – a randomised phase III trial, BMC Cancer 2011 Apr 17
  • Carlino MS, Fogarty GB, Long GV. Treatment of melanoma brain metastases: a new paradigm. Cancer J. 2012 Mar-Apr

Editorials

  • Thompson JF, Hong A, Fogarty G. Publication and Interpretation of Clinical Trial Results: The Need for Caution; Annals of Surgical Oncology 2012 Jun

Letters

  • Burmeister BH, Henderson MA, Thompson JF. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial- Author’s reply. Lancet Oncol. 2012 Jun

Oral Presentations

  • Wang T. et al. An open-label, single-arm, phase I/II, multicenter study to evaluate the safety and efficacy of the combination of dabrafenib (GSK2118436), trametinib (GSK1120212) and palliative radiotherapy for the treatment of extra-cranial metastases in patients with BRAF mutant metastatic melanoma, Australia and New Zealand Melanoma Trials Group Annual Scientific Meeting, 10th December 2012, Sydney, Australia [Oral Presentation]
  • M Henderson. A randomised clinical trial of surgery versus surgery plus adjuvant radiotherapy for regional control in patients with completely resected macroscopic nodal metastatic melanoma, ANZMTG ASM, December 2012, Sydney, Australia (Oral Presentation)
  • A Hong. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - A randomised phase III trial & overview of current sub-studies, ANZMTG ASM, December 2012, Sydney, Australia (Oral Presentation)
  • M Foote, A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck, ANZMTG ASM, December 2012, Sydney, Australia (Oral Presentation)
  • R Saw, Vitamin D following primary treatment of melanoma at high risk of recurrence: A pilot placebo controlled randomised phase II trial, ANZMTG ASM, December 2012, Sydney, Australia (Oral Presentation)
  • M Brown, Phase I Study of Safety and Immune Effects of an Escalating Dose of Autologous GD2 Chimeric Antigen Receptor-Expressing Peripheral Blood T Cells in Patients with Metastatic Melanoma, ANZMTG ASM, December 2012, Sydney, Australia (Oral Presentation)
  • P Guitera, A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna when staged surgical excision with 5mm margins is not possible, is refused or fails, ANZMTG ASM, December 2012, Sydney, Australia (Oral Presentation)
  • M Foote, Radiotherapy followed by selective nodal dissection for high volume regional melanoma, ANZMTG ASM, December 2012, Sydney, Australia (Oral Presentation)
  • A Spillane, Inguinal or Ilio-inguinal Lymph Node Dissection for patients with metastatic melanoma to groin lymph nodes and no evidence of pelvic disease on PET / CT Scan –  A randomised phase III trial, ANZMTG ASM, December 2012, Sydney, Australia (Oral Presentation)
  • C Allan, Lymphoedema prevention following lymph node dissection for metastatic melanoma, ANZMTG ASM, December 2012, Sydney, Australia (Oral Presentation)
  • M Moncrieff, Melanoma Excision Margins Trial, ANZMTG ASM, December 2012, Sydney, Australia (Oral Presentation)
  • G Fogarty. Five current ANZMTG trials will help define the role of Radiotherapy in Melanoma, 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress, November 2012, Barcelona, Spain (Oral presentation) – Awarded Best Oral Presentation
  • Dieng M., Watts C., Kasparian N.A., Morton R., Mann G., Cust A. Improving cancer risk understanding:  A systematic review of educational interventions for people with, or at high risk of, cancer. Asia-Pacific Journal of Clinical Oncology 2012, 8 (Suppl. 3):343. World Congress of Psycho-Oncology, 13-15 November 2012, Brisbane, Australia [Oral presentation]
  • G Fogarty. Whole Brain Radiotherapy Following Local Treatment of 1-3 Intracranial Metastases of Melanoma – A Phase III Trial (ANZMTG 01/07; TROG 08/05), Scott Kirkbride Melanoma Research Centre (SKMRC) Melanoma Conference, October 2012, Perth, Australia (Oral presentation)
  • K Drummond. Whole Brain Radiotherapy Following Local Treatment of 1-3 Intracranial Metastases of Melanoma – A Phase III Trial (ANZMTG 01/07; TROG 08/05), Victorian Cooperative Oncology Group (VCOG), October 2012, Melbourne, Australia (Oral presentation)
  • J Nobes. Radiotherapy and Melanoma, UK Melanoma Study Group, October 2012, London, UK (Oral presentation)
  • Dieng M., McLoone J.K., Meiser B., Butow P.N., Barlow-Stewart K., Cust A.E., Mann G.J., Menzies S, Kasparian N.A. Development and pilot testing of a psycho-educational intervention for Australians at high risk of melanoma. Sydney Cancer Conference, September 2012, Sydney Australia. [Oral presentation]
  • G Fogarty. Whole Brain Radiotherapy Following Local Treatment of 1-3 Intracranial Metastases of Melanoma – A Phase III Trial (ANZMTG 01/07; TROG 08/05), The Royal Australian and New Zealand College of Radiologists, Faculty of Radiation Oncology Annual Scientific Meeting (RANZCR FRO ASM), July 2012, Cairns, Australia (Oral presentation)
  • E Paton. Whole Brain Radiotherapy Following Local Treatment of 1-3 Intracranial Metastases of Melanoma – A Phase III Trial (ANZMTG 01/07; TROG 08/05), Trans Tasman Radiation Oncology Group Annual Scientific Meeting (TROG ASM), May 2012, Darwin, Australia (Oral presentation)
  • M Foote. A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (ANZMTG 01.09; TROG 08.09), Trans Tasman Radiation Oncology Group (TROG) Annual Scientific Meeting, May 2012, Darwin, Australia (Oral presentation)
  • P Guitera, Lentigo Maligna: multidisciplinary approach and proposition of a 2nd line protocol, 3rd World Congress of Dermoscopy, May 2012, Brisbane, Australia (Oral Presentation)
  • R Morton, Whole Brain Radiotherapy Following Local Treatment of 1-3 Intracranial Metastases of Melanoma – A Phase III Trial, Oxford University Oncology Clinical Trials Group (OCTO), January 2012, Oxford, UK (Oral presentation)

Poster Presentations

  • V Steel, E Paton, E Lin, A Lucas, G Fogarty. It’s all about the numbers!  Strategies to Increase Melanoma Trial Participation, Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting, November 2012, Brisbane, Australia (Poster presentation)
  • V Steel, E Paton, E Lin, A Lucas, G Fogarty. It’s all about the numbers!  Strategies to Increase Melanoma Trial Participation, Scott Kirkbride Melanoma Research Centre (SKMRC) Melanoma Conference, October 2012, Perth, Australia (Poster presentation)

Audiovisual Recordings

Return to top

2011

Oral Presentations 

  • J Winstanley, Melanoma Quality of Life activities and update; ANZMTG 01.09RP Improving Quality of Life measurement for melanoma patients: Validity and reliability study of QoL instruments in a NSW population (MELQOL) & EORTC Melanoma Module (MELMOD), ANZMTG ASM, November 2011, Melbourne, Australia (Oral Presentation)
  • M Henderson, ANZMTG 01.02 A randomised clinical trial of surgery versus surgery plus adjuvant radiotherapy for regional control in patients with completely resected macroscopic nodal metastatic melanoma (Adjuvant Rx), ANZMTG ASM, November 2011, Melbourne, Australia (Oral Presentation)
  • G Fogarty, ANZMTG 01.07 Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - A randomised phase III trial (WBRTMel), ANZMTG ASM, November 2011, Melbourne, Australia (Oral Presentation)
  • R Morton, ANZMTG 01.07 WBRT Mel – Health economic evaluation of WBRT sub-study, ANZMTG ASM, November 2011, Melbourne, Australia (Oral Presentation)
  • R Morton, ANZMTG 01.09 Vitamin D following primary treatment of melanoma at high risk of recurrence: A pilot placebo controlled randomised phase II trial (Mel-D), ANZMTG ASM, November 2011, Melbourne, Australia (Oral Presentation)
  • M Foote, ANZMTG 02.09 A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (RTN2), ANZMTG ASM, November 2011, Melbourne, Australia (Oral Presentation)
  • J Thompson, JWCI: A Phase III, Randomized Trial of Surgical Resection with BCG versus Best Medical Therapy as Initial Treatment in Stage IV Melanoma (Stage IV protocol), ANZMTG ASM, November 2011, Melbourne, Australia (Oral Presentation)
  • J Thompson, UK Melanoma Study Group Melanoma Margins Trial (MelMarT), ANZMTG ASM, November 2011, Melbourne, Australia (Oral Presentation)
  • Whole Brain Radiotherapy Following Local Treatment of 1-3 Intracranial Metastases of Melanoma – A Phase III Trial (ANZMTG 01/07; TROG 08/05), held in Tampa, USA in November 2011
    Conveners: G Fogarty, E Paton
    Facilitators: G Fogarty, E Paton
    Oral Presentations: G Fogarty, J Thompson, E Paton
  • Fogarty G. et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial Royal Australian and New Zealand College of Radiologists (RANZCR) Annual Scientific Meeting, October 2011, Melbourne, VIC (Oral presentation)
  • Foote M. et al. A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck Australian Society of Otolaryngology Head and Neck Surgery Meeting, September 2011, Singapore (Oral presentation)
  • Fogarty G. et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting, August 2011, Adelaide, SA (Oral presentation)
  • Dolven Jacobsen, K. et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial; European Post-ASCO Meeting, July 2011, Munich, Germany (Oral presentation)
  • Middleton M. et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. UK Melanoma Study Group Summer Meeting, June 2011, Manchester, UK (Oral presentation)
  • Byrne M et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. Trans Tasman Radiation Oncology Group (TROG) Annual Scientific Meeting, April 2011, Adelaide, Australia (Oral presentation)
  • Foote M et al. A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (RTN2). Trans Tasman Radiation Oncology Group (TROG) Annual Scientific Meeting, April 2011, Adelaide, Australia. (Oral presentation)
  • Nowak A et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. WA Neurosurgical Grand Round meeting, Sir Charles Gairdner Hospital, March 2011, Perth, Australia (Oral presentation)
  • Fogarty G et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. Sydney Neuro-oncology Group (SNOG) Executive Meeting, RNSH, February 2011, Sydney, Australia (Oral presentation)

Poster Presentations

 

  • G Fogarty; E Paton; A. Hong; B. Shivalingam; K. Dolven Jacobsen; B. Burmeister; J. Thompson. Whole Brain Radiotherapy Following Local Treatment of 1-3 Intracranial Metastases of Melanoma – A Phase III Trial (ANZMTG 01/07; TROG 08/05), Society of Melanoma Research, November 2011, Florida USA (Poster presentation)
  • M.Gonzalez, M.Cronin, A.Hong, G.Fogarty, A.Grierson, H.Dhillon, J.F.Thompson, J.Vardy, Quality assurance of data collection of neurocognitive function testing in a pilot whole brain radiotherapy clinical trial for metastatic melanoma, Society of Melanoma Research, November 2011, Florida USA (Poster presentation)
  • V Jakrot, E Paton, G Fogarty, B Shivalingam, A Hong, R Scolyer, G Mann, J Thompson. Melanoma Brain Metastases Trials and Bio-specimen Banking; Society of Melanoma Research, November 2011, Florida USA (Poster presentation) – Awarded Best Poster Presentation
  • L Pearce, E Paton, N Ware, J Thompson. The importance of a melanoma clinical nurse consultant; COSA ASM 2011, Perth, November 2011 (Poster presentation)
  • E Paton, P Wagland, G Fogarty, J Thompson. The challenges of conducting collaborative group research within Australia; COSA ASM 2011, Perth, November 2011 (Poster presentation)
  • E Paton, G Fogarty, A Hong, C Mandel, H Fuentes, H Dhillon, G Hruby, R Scolyer, A Nowak, J Thompson. ANZMTG 01.07 WBRT Mel Trial – 2011 Quality Assurance; COSA ASM 2011, Perth, November 2011 (Poster presentation)
  • E Paton, G Fogarty, A Hong, J Thompson, J Nobes. Innovative strategies to enhance recruitment for melanoma clinical trials; COSA ASM 2011, Perth, November 2011 (Poster presentation)
  • G Fogarty, E Paton, A Hong, B Shivalingam, K Dolven Jacobsen, B Burmeister, J Thompson. Whole Brain Radiotherapy Following Local Treatment of 1-3 Intracranial Metastases of Melanoma – A Phase III Trial (ANZMTG 01/07; TROG 08/05); COSA ASM 2011, Perth, November 2011 (Poster presentation)
  • M.Gonzalez, M.Cronin, A.Hong, G.Fogarty, A.Grierson, H.Dhillon, J.F.Thompson, J.Vardy, Quality assurance of data collection of neurocognitive function testing in a pilot whole brain radiotherapy clinical trial for metastatic melanoma, COSA ASM 2011, Perth, November 2011 (Poster presentation)
  • V Jakrot, E Paton, G Fogarty, B Shivalingam, A Hong, R Scolyer, G Mann, J Thompson. Melanoma Brain Metastases Trials and Bio-specimen Banking; 9th Annual Australasian Biospecimen Network Association Meeting, Perth, November 2011 (Poster presentation)
  • Fogarty G. et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting, August 2011, Adelaide, SA (Poster presentation)

Audiovisual Recordings

  • “Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trial – Why we need it” 
    YouTube: http://www.youtube.com/watch?v=7gxrA7vNWPE (CINSW Ethics Approval Nov2011)

2010

Oral Presentations 

  • Cochran A. JWCI: A Phase III, Randomized Trial of Surgical Resection With or Without BCG Versus Best Medical Therapy as Initial Treatment in Stage IV Melanoma, ANZMTG ASM, November 2010, Sydney, Australia (Oral Presentation)
  • Moncrieff M. UK Melanoma Study Group, Randomised Controlled Trial of 1cm vs 2cm Excision Margins for 1-4mm Thickness Primary Invasive Cutaneous Melanoma, ANZMTG ASM, November 2010, Sydney, Australia (Oral Presentation)
  • Foote M. ANZMTG 01.09 / TROG 08.09 A randomised trial of post-operative radiation therapy following wide excision of neurotropic melanoma of the head and neck, ANZMTG ASM, November 2010, Sydney, Australia (Oral Presentation)
  • Brown M. CARPETS: Phase I Study of Safety and Immune Effects of an Escalating Dose of Autologous GD2 Chimeric Antigen Receptor-Expressing Peripheral Blood T Cells in Patients with Metastatic Melanoma, ANZMTG ASM, November 2010, Sydney, Australia (Oral Presentation)
  • Fogarty G et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. Meeting of Interdisciplinary Melanoma / Skin Cancer Centres, November 2010, Sydney, Australia (Oral presentation)
  • Fogarty G et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. ANZMTG WBRT Investigator Meeting and Trial Update, November 2010, Sydney, Australia (Oral presentation)
  • Fogarty G et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. Trans Tasman Radiation Oncology Group (TROG) Trials Review Meeting, October 2010, Melbourne, Australia. (Oral presentation)
  • Fogarty G et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. The Royal Australian and New Zealand College Radiologists (RANZCR) ASM, October 2010, Perth, Australia. (Oral presentation)
  • Paton, E. ANZMTG overview and activities. PC4 Concept Development Workshop, October 2010, Sydney, Australia. (Oral presentation)
  • Foote M. A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (RTN2 ). Melanoma Institute Australia Research Meeting, October 2010, North Sydney, Australia. (Oral presentation)
  • Winstanley J. et al. ANZMTG RP 01.09: MELQOL - Improving the measurement of Quality of Life in an Australian melanoma population. European Organisation for Cancer and Treatment of Cancer (EORTC) Quality of Life Research Meeting, September 2010, Leipzig, Germany. (Oral presentation and Workshop)
  • Fogarty G et al. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. UK Melanoma Study Group Summer Meeting, June 2010, University of Leeds, UK. (Oral presentation)

Poster Presentations 

  • Fogarty G. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase III trial. Clinical Oncological Society of Australia Annual Scientific Meeting, November 2010, Melbourne, Australia (Poster presentation)
  • V.Jakrot et al. Recruitment And Follow-Up Strategies For A Large Melanoma Sentinel Node Trial With 10 Year Follow-Up - A Coordinator's View From A Site Perspective. Meeting of Interdisciplinary Melanoma / Skin Cancer Centres, November 2010, Sydney, Australia (Poster presentation) (Awarded Best Poster SMR 2010)
  • V.Jakrot et al. Recruitment And Follow-Up Strategies For A Large Melanoma Sentinel Node Trial With 10 Year Follow-Up - A Coordinator's View From A Site Perspective. Clinical Oncological Society of Australia Annual Scientific Meeting, November 2010, Melbourne, Australia. (Poster presentation)
  • V.Jakrot et al. Recruitment And Follow-Up Strategies For A Large Melanoma Sentinel Node Trial With 10 Year Follow-Up - A Coordinator's View From A Site Perspective. The 7th International Sentinel Node Society Meeting, November 2010, Yokohama, Japan. (Poster presentation)

Return to top

2009

Conference Abstracts/Proceedings

  • Henderson M., Burmeister B., Thompson J., Di Iulio J., Fisher R., Hong A., Scolyer R., Shannon K., Hoesktra H., Ainslie J. ANZMTG 01.02/TROG 02.01 Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial. Journal of Clinical Oncology (Meeting Abstracts). 2009; 27: 18S. (Abstract article)

Oral Presentations 

  • Fogarty G. and Shivalingam, B. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase II trial. Annual Scientific Meeting for the Asia Pacific College of Neurosurgeons, September 2009, Alice Springs, Australia. (Oral presentation)
  • Winstanley J. ANZMTG RP 01.09: MELQOL - Improving the measurement of Quality of Life in an Australian melanoma population. European Organisation for Cancer and Treatment of Cancer (EORTC) Quality of Life Research Meeting, September 2009, Pamplona, Spain. (Oral presentation)
  • Winstanley J., Paton E., King M., Thompson J. ANZMTG RP 01.09: MEL QOL - Improving the measurement of Quality of Life in an Australian melanoma population. 7th World Congress on Melanoma & 5th Congress of the European Association of Dermato-Oncology (EADO) Conference, May 2009, Vienna, Austria. (Oral presentation)
  • Paton E., Winstanley J., Thompson J., Morton R. Overview of the Australia and New Zealand Melanoma Trials Group (ANZMTG) research activities. 7th World Congress on Melanoma & 5th Congress of the European Association of Dermato-Oncology (EADO) Conference, May 2009, Vienna, Austria. (Oral presentation)
  • Fogarty G. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase II trial. 7th World Congress on Melanoma & 5th Congress of the European Association of Dermato-Oncology (EADO) Conference, May 2009 Vienna, Austria. (Oral presentation)
  • Burmeister B., Paton E., Hruby G., Carruthers S., Thompson J., Smithers M., Henderson M., Meakin J,. Does Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck Decrease the Risk of Local Recurrence? 7th World Congress on Melanoma & 5th Congress of the European Association of Dermato-Oncology (EADO) Conference, May 2009 Vienna, Austria. (Oral presentation)
  • Henderson M., Burmeister B., Thompson J., Di Iulio J., Fisher R., Hong A., Scolyer R., Shannon K., Hoesktra H., Ainslie J. ANZMTG 01.02/TROG 02.01 Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial. American Society of Clinical Oncology (ASCO) Annual Meeting, May 2009, Florida, USA. (Oral presentation)
  • Fogarty G., Paton E. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase II trial. Trans Tasman Radiation Oncology Group (TROG) Annual Scientific Meeting, March 2009, Shoal Bay, Australia. (Oral presentation)
  • Paton, E. A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (RTN2). World Melanoma Congress, Vienna. (Oral presentation)

Poster Presentations 

  • Fogarty G., Morton R., Thompson, J., Hong A. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase II trial. 3rd Annual International Melanoma Centres Meeting, November 2009, Berlin, Germany. (Poster presentation)
  • Fogarty G., Morton R., Thompson, J., Hong A. Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – a randomised phase II trial. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting, November 2009, Gold Coast, Australia. (Poster presentation)

Return to top
© 2016 Australia and New Zealand Melanoma Trials Group